Evidence map›Paper›PMID 35010137›Full record

ArticleFoods (Basel, Switzerland)2021

Does the Food Ingredient Pectin Provide a Risk for Patients Allergic to Non-Specific Lipid-Transfer Proteins?

Hanna Steigerwald, Frank Blanco-Perez, Melanie Albrecht, Caroline Bender, Andrea Wangorsch, Hans-Ulrich Endreß, Mirko Bunzel, Cristobalina Mayorga, Maria José Torres, Stephan Scheurer and 1 more

Registry-linked trialAbstract read
In one paragraph

Article in Foods (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06558526 (Analysis of the Clinical Efficacy and Immunomodulatory Effect of Pectin in LTP Allergic Patients Through a Placebo-controlled Intervention Study and Long-term Follow-up), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06558526 narecruitingnot on this mapstarted 2025, after this paper: background citation

Analysis of the Clinical Efficacy and Immunomodulatory Effect of Pectin in LTP Allergic Patients Through a Placebo-controlled Intervention Study and Long-term Follow-up

TypeinterventionalSponsorFundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludRan2025 to 2026Enrolled62ConditionsFood AllergyArmsApple pectin (DE 57%), Placebo
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hanna SteigerwaldPaul-Ehrlich-Institut (PEI), Federal Institute for Vaccines and Biomedicines, 63225 Langen, Germany.ORCID 0000-0002-4219-6270
Frank Blanco-PerezPaul-Ehrlich-Institut (PEI), Federal Institute for Vaccines and Biomedicines, 63225 Langen, Germany.ORCID 0000-0003-3092-539X
Melanie AlbrechtPaul-Ehrlich-Institut (PEI), Federal Institute for Vaccines and Biomedicines, 63225 Langen, Germany.
Caroline BenderKarlsruhe Institute of Technology (KIT), Institute of Applied Biosciences, 76131 Karlsruhe, Germany.
Andrea WangorschPaul-Ehrlich-Institut (PEI), Federal Institute for Vaccines and Biomedicines, 63225 Langen, Germany.ORCID 0000-0002-5184-5455
Hans-Ulrich EndreßHerbstreith & Fox KG, Neuenbürg, Turnstrasse 37, 75305 Neuenburg, Germany.
Mirko BunzelKarlsruhe Institute of Technology (KIT), Institute of Applied Biosciences, 76131 Karlsruhe, Germany.ORCID 0000-0003-0462-8076
Cristobalina MayorgaAllergy Unit, IBIMA-Regional University Hospital of Malaga-UMA, 29010 Malaga, Spain.ORCID 0000-0001-8852-8077
Maria José TorresAllergy Unit, IBIMA-Regional University Hospital of Malaga-UMA, 29010 Malaga, Spain.
Stephan ScheurerPaul-Ehrlich-Institut (PEI), Federal Institute for Vaccines and Biomedicines, 63225 Langen, Germany.ORCID 0000-0002-2859-562X
Stefan ViethsPaul-Ehrlich-Institut (PEI), Federal Institute for Vaccines and Biomedicines, 63225 Langen, Germany.

Funding

Andalusian Regional Ministry of Health PE-0039-2018Andalusian Regional Ministry of Health RC-004-2021Federal Ministry for Economic Affairs and Energy AiF20528Federal Ministry of Education and Research BMBF-ERA 01EA1901Joint Programming Initiative a Healthy Diet for a Healthy Life (DIFAMEM) AC18/00031
6 · The paper itself

Abstract

Pectin, a dietary fiber, is a polysaccharide that is widely used in food industry as a gelling agent. In addition, prebiotic and beneficial immunomodulatory effects of pectin have been demonstrated, leading to increased importance as food supplement. However, as cases of anaphylactic reactions after consumption of pectin-supplemented foods have been reported, the present study aims to evaluate the allergy risk of pectin. This is of particular importance since most of the pectin used in the food industry is extracted from citrus or apple pomace. Both contain several allergens such as non-specific lipid transfer proteins (nsLTPs), known to induce severe allergic reactions, which could impair the use of pectins in nsLTP allergic patients. Therefore, the present study for the first time was performed to analyze residual nsLTP content in two commercial pectins using different detection methods. Results showed the analytical sensitivity was diminished by the pectin structure. Finally, spiking of pectin with allergenic peach nsLTP Pru p 3 led to the conclusion that the potential residual allergen content in both pectins is below the threshold to induce anaphylactic reactions in nsLTP-allergic patients. This data suggests that consumption of the investigated commercial pectin products provides no risk for inducing severe reactions in nsLTP-allergic patients.

Indexed as

food allergynon-specific lipid transfer proteinnsLTPpectinPru p 3

Identifiers

PMID35010137
PMCPMC8750200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.